As a result, his company's revenue (set to double this year, to $100 million) is fueled almost completely by CrossFit's rampant proliferation. Meanwhile, a burgeoning ecosystem of other businesses has risen up to cater to these squatting, thrusting fiefdoms. There are multiple apparel companies; food and beverage companies (serious CrossFitters are often serious about the Paleo Diet); businesses that cater specifically to box owners, with iPad apps that track workouts and manage membership rolls; business consultants who show box owners how to increase their revenue. A Web design firm specializes in CrossFit box sites. There are even two print magazines, The Box and WOD Talk.
The WHO trial (so named because the international team of principal investigators contained World Health Organization members) tested the potential of clofibrate, a “pre-statin” cholesterol-lowering agent, to reduce heart attack morbidity and mortality. The investigators ultimately concluded that clofibrate "cannot be recommended as a lipid-lowering drug for community-wide primary prevention of ischaemic heart disease.” Nevertheless, clofibrate remained in use until 2002, when it was pulled for increasing cancer rates. In their review of studies such as the WHO trial, Uffe Ravnskov and David Diamond observe, “Despite the largely disappointing findings from 50 years of cholesterol lower[ing] trials, the indictment and conviction of cholesterol as the causal agent in CVD [cardiovascular disease] has stood the test of time. … [Yet] the grand effort to reduce cholesterol as a strategy to improve health has failed.”